Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT06642909
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT06541678
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Bruxelles, Bruxelles-Capitale, Belgium
Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT06525948
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 132
- Registration Number
- NCT06509243
- Locations
- 🇵🇱
SUM, Zabrze, Poland
Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT06424639
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT06364319
Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Virginia G. Kaklamani
- Target Recruit Count
- 24
- Registration Number
- NCT06246786
- Locations
- 🇺🇸
Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Conditions
- Acute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmHematopoietic and Lymphoid System NeoplasmMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeMyeloproliferative NeoplasmNon-Hodgkin LymphomaChronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateDrug: CyclophosphamideDrug: CyclosporineProcedure: Diagnostic ImagingProcedure: EchocardiographyDrug: Fludarabine PhosphateProcedure: Multigated Acquisition ScanDrug: Mycophenolate MofetilOther: Survey AdministrationDrug: ThiotepaRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06013423
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA
- Conditions
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06009497
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06004752
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.